The Eradication Of Cancer And Cancer Essay

Triple-negative breast cancer occurs when cells lack estrogen receptors and progesterone receptors from not having an excess of the HER2 protein (Rosen, 2011). The gene HER2 helps cells grow, divide, and repair; this spreads the disease faster. HER2-positive breast cancer becomes a more aggressive cancer and has a higher risk for recurrence (Chen, 2010).Typically found in younger women and African-American women; this cancer grows and spreads quickly (Rosen, 2011).

The baseline cohort was retrieved from the SEER9 database and consisted of females diagnosed with breast cancer as a first primary cancer identified by diagnosis codes from the International Classification of Diseases for Oncology

An effective breast cancer treatment in some women can be traced to the root of the disease. Some of the most aggressive form of breast cancers are caused by a transmembrane receptor protein known as Human Epidermal Growth Factor Receptor 2 (HER2) which is a member of the HER family of receptor tyrosine kinase. Approximately 20,000 HER2 receptor are normally expressed on surface of healthy breast cell however, in about 25% of breast cancer cells the HER2 protein is overexpressed resulting in tumour cells with as many as over 2 million receptors present on their surface. This cancer is known as HER2 positive (HER2+). The effect of HER2 overexpression is an increase in receptor mediated intracellular signalling causing the cell

As the cells change, it begins to divide rapidly causing a tumor to form. The term “breast cancer” refers to a malignant tumor that has developed from cells in the breast. Breast cancer can begin in different areas of the breast, or in some cases, the tissues in between. There are many different types of breast cancer, including non-invasive, invasive, recurrent, metastatic breast cancer, as well as the intrinsic or molecular subtypes of breast cancer. Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality.

Breast cancer constitutes the second most prevalent cancer most common among women of the world with an estimated 1.62 million reported cases in 2012 which constitutes 25% of all cancer cases and ranks fifth among mortality due to cancer (Ferlay et al., 2015). In the United States, according to American Cancer Society an

A recent prospective study has demonstrated a substantial rate of discordance in hormone receptor status (40% discordance in ER/PgR status and 8% discordance in Her2 status) between primary and suspected metastatic lesions in women with breast cancer. This study has also linked changes in hormone receptor status with impact on management, and proved that 20% of patients had a significant change in their management plan (Simmons et al,

Cancer of the breast is the most common type of non-skin cancer affecting women. It also comes second after lung cancer in the number of deaths among the African-American population in 2017; the American Cancer Society estimated that there would be approximately 252,710 new cases of breast cancer which is considered invasive that will be diagnosed in the United States. More so, nearly 63,410 new cases of (CIS) carcinoma in situ will be detected, and approximately 40,610 women will depart this life as a result of cancer of the breast(Siegel, Miller, & Jemal, 2015).In the United States, the incidence of cancer of the breast is not similar among the African America women and the white. Such that, it has been noted that the

Drug discovery is expensive and challenging. One such challenge is identifying clinically active cancer targets out of a huge number of biomolecules that are known to have a role in cancer initiation and progression. Below I have outlined the key information that should be gathered about a novel drug target, the experiments that are required to validate such a target, and discussed what needs to be considered when deciding whether a target has been validated.

Breast cancer isn’t a death sentence as it was before. Women used to fear being diagnosed with this disease because there was no cure for it. Breast cancer has been around for centuries, but the advancement of medicine has increased the chances of survival, and in the future the improvements will be even greater.

According to the American Cancer Society, “About 12 percent of women in the Unites States will develop breast cancer during their lifetime. The American Cancer Society study also found that breast cancer in the US for 2014 are about 232,670 new cases of invasive breast cancer will be diagnosed in women, 62,570 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is non-invasive and is the earliest form of breast cancer). About 40,000 women will die from breast cancer”. (Society)

Breast cancer is a complex and heterogeneous disease caused by both genetic and non-genetic risk factors. These factors include, mutations in breast cancer-associated genes 1 and 2 (BRCA1 and BRCA2) [1]; loss or aberrant expression of the estrogen receptor (ER) [2]; human epidermal growth factor receptor (HER2) overexpression [3] ; lack of ER, progesterone receptor (PR), and epidermal growth factor receptor (EGFR) expression[4] ; high levels of receptor for the insulin-like growth factor receptor 1 (IGF-1R[5]; and expression of microRNA (miRNA) [6]. In addition to genetic alterations (gene amplifications, deletions, point mutations, and chromosome rearrangements), epigenetic changes (methylation and/or acetylation) of the genome play an important role in breast carcinogenesis. For example, methylation of RASSF1A, BRCA1, and estrogen receptor α (ERα) is associated with breast tumorigenesis and metastasis [7]. The inactivation of tumor suppressor proteins that lead to tumor cell growth and survival are another mechanism of breast cancer development [8]. These genes are inactivated by a variety of mechanisms, including chromosomal deletions, intragenic mutations, proteolysis, and loss of epigenetic modifications [9]. The best-characterized tumor suppressor protein is p53. In breast cancer, p53 mutation or downregulation is associated with an adverse prognosis [10]. Other tumor suppressor proteins in breast cancer include PTEN [11], p16[12], the retinoblastoma gene[13], and

Female breast cancer is the second most common cancer in the world with over 1.6 million cases diagnosed in 2012 (Australian Bureau of Statistics, 2012). Deaths from breast cancer within Australia have increased by 380% from 2003 to 2012 (ABS, 2012)(Smith et al., 2012). An individual’s risk of developing breast cancer increases dramatically with age until 50 where it plateaus giving women a 1:8 lifetime risk (Kamangar et al., 2006)(Davies, 2012). There are several varieties of breast cancer with the most frequent being invasive ductal carcinoma (Fernandez-Vega et al., 2013).

Breast cancer is the most common cause of cancer-related death among females in the world. It is known for “have both a genetic and non-genetic etiology” (Milne et al., 2010). It involves a combination of several factors- such as “genetic, environmental and behavioral risk factors”- that are unique to each individual (Nickels et al., 2013). This type of cancer is represented by a malignant tumor manifested in breast cells such as the line duct and line lobules cells, just to name a few. Because there are different types of breast cancer, it is harder to create an effective treatment or therapy that would lower or prevent its death rates. Despite advances in technology but lack of monetary support, there is a higher prevalence in African countries (U.S. breast cancer statistics, 2013). It has been found that “two thirds of breast tumors express estrogen receptors” (Lopez-Tarruella & Schiff, 2007). Because of this, growth factor receptor signaling and hormone therapies have been shown as promising treatments to prevent and/or to find a cure for this cancer.

Breast cancer exists today as a vicious disease which has multiple facets for killing its host. The largest indicator of survival rate is length of time alive after diagnosis with the disease, and then whether or not the disease has metastasized to a new location in the body. For breast cancer patients, the 5-year survival rate of patients below Stage 4 is 90%. The stages below the 4 stage represent the stages where the breast cancer has not metastasized into other regions of the body. When breast cancer metastasizes into another region of the body, the 5-year survival rate of these individuals drops to 22%. The most common places of metastasis include the brain, liver, and lungs. The goal of studying cell line 231BR is that of

Cancer is one of the leading causes of death worldwide as it can develop in almost any organ or tissue. Significant advances in understanding the cellular basis of cancer and the underlying biological mechanisms of tumour has been vastly improved in the recent years (Jiang et al. 1994). Cancer is a genetic disease which requires a series of mutation during mitosis to develop, its characteristics can be associated with their ability to grow and divide abnormal cells uncontrollable while in the mean time invade and cause nearby blood vessels to serve its need. Even though many people are affected by cancer today, the abilities which cancer cells have make it hard to find a single effective treatment for cancer. The focus of research now lies